BBIO Q2 2023 Earnings — BridgeBio Pharma, Inc. Revenue & Financial Results | Market Cap Arena

BBIOBridgeBio Pharma, Inc.

$14B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-97.8% YoY

Gross Profit

$1M63.5% margin

Operating Income

-$146M-8903.0% margin

Net Income

-$158M-9622.1% margin

EPS (Diluted)

$-0.98

QoQ Revenue Growth

-10.1%

Cash Flow

Operating Cash Flow

-$113M

Free Cash Flow

-$114M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$504M

Total Liabilities

$1.9B

Stockholders' Equity

-$1.4B

Cash & Equivalents

$302M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$74M	-97.8%
Gross Profit	$1M	$73M	-98.6%
Operating Income	-$146M	-$80M	-82.2%
Net Income	-$158M	-$10M	-1502.1%